Literature DB >> 29221258

Neoadjuvant DCF vs. ACF for resectable oesophageal squamous cell carcinoma.

Vasiliki Michalarea1, Elizabeth C Smyth1.   

Abstract

Entities:  

Year:  2017        PMID： 29221258      PMCID： PMC5708483          DOI： 10.21037/jtd.2017.08.148

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  17 in total

1.  Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial.

Authors: 
Journal:  Lancet       Date:  2002-05-18       Impact factor: 79.321

2.  Oesophageal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Authors:  F Lordick; C Mariette; K Haustermans; R Obermannová; D Arnold
Journal:  Ann Oncol       Date:  2016-09       Impact factor: 32.976

3.  Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus.

Authors:  Michael Stahl; Martin Stuschke; Nils Lehmann; Hans-Joachim Meyer; Martin K Walz; Siegfried Seeber; Bodo Klump; Wilfried Budach; Reinhard Teichmann; Marcus Schmitt; Gerd Schmitt; Claus Franke; Hansjochen Wilke
Journal:  J Clin Oncol       Date:  2005-04-01       Impact factor: 44.544

4.  Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102.

Authors:  Laurent Bedenne; Pierre Michel; Olivier Bouché; Chantal Milan; Christophe Mariette; Thierry Conroy; Denis Pezet; Bernard Roullet; Jean-François Seitz; Jean-Philippe Herr; Bernard Paillot; Patrick Arveux; Franck Bonnetain; Christine Binquet
Journal:  J Clin Oncol       Date:  2007-04-01       Impact factor: 44.544

5.  Feasibility of Preoperative Chemotherapy with Docetaxel, Cisplatin, and 5-Fluorouracil versus Adriamycin, Cisplatin, and 5-Fluorouracil for Resectable Advanced Esophageal Cancer.

Authors:  Osamu Shiraishi; Makoto Yamasaki; Tomoki Makino; Masaaki Motoori; Hiroshi Miyata; Masayuki Shinkai; Yutaka Kimura; Motohiro Hirao; Kazumasa Fujitani; Shigeyuki Tamura; Kenji Kobayashi; Masahiko Yano; Yuichiro Doki; Takushi Yasuda
Journal:  Oncology       Date:  2016-12-02       Impact factor: 2.935

6.  Global incidence of oesophageal cancer by histological subtype in 2012.

Authors:  Melina Arnold; Isabelle Soerjomataram; Jacques Ferlay; David Forman
Journal:  Gut       Date:  2014-10-15       Impact factor: 23.059

7.  Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group.

Authors:  Eric Van Cutsem; Vladimir M Moiseyenko; Sergei Tjulandin; Alejandro Majlis; Manuel Constenla; Corrado Boni; Adriano Rodrigues; Miguel Fodor; Yee Chao; Edouard Voznyi; Marie-Laure Risse; Jaffer A Ajani
Journal:  J Clin Oncol       Date:  2006-11-01       Impact factor: 44.544

8.  Trends in esophageal cancer incidence by histology, United States, 1998-2003.

Authors:  Katrina F Trivers; Susan A Sabatino; Sherri L Stewart
Journal:  Int J Cancer       Date:  2008-09-15       Impact factor: 7.396

Review 9.  Oesophageal cancer.

Authors:  Elizabeth C Smyth; Jesper Lagergren; Rebecca C Fitzgerald; Florian Lordick; Manish A Shah; Pernilla Lagergren; David Cunningham
Journal:  Nat Rev Dis Primers       Date:  2017-07-27       Impact factor: 52.329

10.  Integrated genomic characterization of oesophageal carcinoma.

Authors: 
Journal:  Nature       Date:  2017-01-04       Impact factor: 49.962
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.